Cubist Pharmaceuticals is a bio-pharmaceutical company focused on the research, commercial­ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.

Product Pipeline

Ceftolozane/tazobactam

Gram-negative CXA-201

for cUTI (complicated urinary tract infection) and
cIAI (complicated intra-abdominal infection)

Pivotal Phase 3 clinical trials of antibiotic candidate ceftolozane/tazobactam, being developed to treat certain infections caused by Gram-negative bacteria, have been completed in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI)…

Dificid

News & Press

22 Apr

Cubist Pharmaceuticals Reports First Quarter 2014 Financial Results

• Total Net Revenues of $261.2 Million, Up 14% Over Q1 2013; U.S. CUBICIN Net Revenues of $212.2 Million, Up 5% Over Q1 2013 • Non-GAAP Adjusted Operating Income of $18.8 Million; GAAP Operating Income of $28.3 Million • Non-GAAP Diluted EPS of $0.10; GAAP Diluted EPS of $0.30

Careers at Cubist

Alice

Meet Alice

Vice President of Medical Affairs, International

Alice was hired in the fall of 2013 as Vice President of Medical Affairs, International, charged with building Cubist’s Medical…

Investor Center

Cubist Pharmaceuticals Loading…
CBST (NASDAQ)